Actuate Therapeutics

Photo of Wall Street street sign with american flags in the background
Biotech

Actuate is latest biotech on Nasdaq after $22.4M IPO

Actuate Therapeutics became the latest biotech to join the Nasdaq this week with a scaled-back IPO that brought in $22.4 million.
James Waldron Aug 15, 2024 4:29am
IPO initial public offering markets raise financing

Cancer-focused Actuate makes 2nd tweak to IPO plans in a week

Jul 24, 2024 4:37am
calculator calculate budget

Actuate halves IPO to $22M, scales back clinical plans

Jul 22, 2024 4:54am
Photo of Wall Street street sign with american flags in the background

Actuate unveils modest $50M IPO to fund cancer drug trials

Jul 17, 2024 4:45am
IPO initial public offering markets raise financing

Clinical-stage cancer biotech Actuate latest to eye summer IPO

May 28, 2024 9:45am
Cancer in newspaper clipping

Actuate raises $22M to expand GSK-3β cancer trial

May 17, 2019 9:14am